Hospital Fernandez de Buenos Aires
Capital Federal, Buenos Aires, Argentina
NCT Number: NCT01080001
This is an observational, non-controlled, multicentric, prospective study planned to be conducted in 66 subjects diagnosed with multiple sclerosis (MS) in 20 centres of Argentina. Fatigue is recognized as one of the most frequent symptoms of MS with a high incidence in MS subjects. The link between fatigue and the degree of disability and other manifestations of the disease, such as depression has not been yet clearly understood. Hence, this study aims to understand the way in which fatigue impairs the quality of life (QoL) of MS subjects. This epidemiologic study can contribute to a better understanding of the way in which fatigue correlates with depression and the intensity with which both situations impact on the QoL of MS subjects.
Looking for future studies?
Notify Me21 year–60 year
All sexes
Observational
Capital Federal, Buenos Aires, Argentina
Fatigue is recognized as one of the most frequent symptoms of MS and its impact on QoL of subjects is high. Fatigue in MS is sometimes considered as a prodromic symptom or as a peculiar symptom that must be differentiated from natural fatigue, pathological fatigue of other chronic diseases; as well as from fatigue caused by the excessive effort in case of gait disorder, spasticity or paresis. The origin of the fatigue symptom in MS is unknown and the cause is likely to be multifactorial. The evaluation of the fatigue is challenging, due to its variability and hence, scales such as Krupp's Fatigue Severity Scale (FSS) has been developed for measuring MS fatigue.
OBJECTIVES
Primary objective:
Secondary objective:
The subjects will be managed with the clinical and therapeutic elements that the treating doctor considers appropriate, without modifying their decisions due to the subject inclusion into the study. The epidemiologic data required by this study will be collected by the investigator from the documents in which each subject visit is registered, whether programmed or not. Once the recruiting period of 12 months is over, the collection of data will continue during the full 24 months period for each subject. The closure of the study will be marked by the follow-up of the last subject who entered the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Each visit conducted from Day 0 (Initial visit) to the closure of the study (End visit at 24 month)
Time frame: Initial visit (Day 0)
Demographic and baseline variables include age, gender, race, baseline disease severity, sleep history, and baseline sleep assessments.
Time frame: Initial visit (Day 0)
Identifying the number of years since disease onset.
Time frame: Each visit conducted from Day 0 (Initial visit) to the closure of the study (End visit at 24 month)
identifying the agents used for the treatment and the treatment duration.
Time frame: Each visit conducted from Day 0 (Initial visit) to the closure of the study (End visit at 24 month)
EDSS >=3,5 disability and EDSS <=3,5 no disability
Time frame: Each visit conducted from Day 0 (Initial visit) to the closure of the study (End visit at 24 month)
Time frame: Each visit conducted from Day 0 (Initial visit) to the closure of the study (End visit at 24 month)
Merck KGaA, Darmstadt, Germany
Industry
Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02914964
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Iowa City, Iowa, United States
View Trial DetailsNCT04833673
Anxiety Disorders, Autoimmune Diseases
Ankara, None Selected, Turkey (Türkiye)
View Trial DetailsNCT03060759
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Boston, Massachusetts, United States
View Trial DetailsNCT02315872
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Cullman, Alabama, United States
View Trial Details